AMA approves PLA code for RenaDx
February 2026—The American Medical Association has approved a new CPT proprietary laboratory analyses code for Personalized Medicine Care Diagnostics’ RenaDx, a comprehensive kidney genetics panel.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Fujirebio launches RUO pTau 217 CSF assay
February 2026—Fujirebio launched the Lumipulse G pTau 217 CSF assay for the fully automated Lumipulse G immunoassay analyzers.
Takara Bio updates its spatial biology product portfolio
February 2026—Takara Bio USA has updated its spatial biology product portfolio with a new class of spatial technology.
Diasorin gets clearance, waiver for fourplex panel
February 2026—Diasorin has received FDA 510(k) clearance and CLIA waiver for its first assay, a flu A/B, RSV, and COVID-19 panel, to be used on the Liaison Nes point-of-care molecular diagnostic platform.
Volta Labs adds WGS apps to Callisto platform
February 2026—Volta Labs is expanding its Callisto sample preparation platform by adding seven validated whole genome sequencing DNA apps.
Illumina gets CMS reimbursement for TSO Comprehensive
February 2026—Illumina announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology Comprehensive test.
CMS finalizes pricing determination for OncoReveal CDx
January 2026—The Centers for Medicare and Medicaid Services has finalized its pricing determination for Pillar Biosciences’ OncoReveal CDx.
NEB launches flu A integrated indexing primer module
January 2026—New England Biolabs released its NEBNext Flu A Integrated Indexing Primer Module, designed to streamline and scale the sequencing of influenza A virus from a range of species and sample types using Oxford Nanopore Technologies platforms.
FDA clears QuidelOrtho Vitros hs troponin I assay
January 2026—The FDA has granted QuidelOrtho Corp. 510(k) clearance for the Vitros hs Troponin I Reagent Pack.
Roche launches next-gen Cobas 6800/8800 systems, software
January 2026—Roche launched Cobas 6800/8800 systems version 2.0 and software version 2.0.1, following FDA 510(k) clearance.